Fabtech Technologies Limited
BSE: FABTECH · Healthcare Research, Analytics & Technology
Snapshot
Unlock Fabtech Technologies Limited's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Fabtech Technologies Ltd is a biopharma engineering firm specialising in end-to-end turnkey solutions for pharmaceutical plants. Their services encompass the entire project lifecycle, including design, engineering, procurement, installation, and regulatory validation.
Business Model
The company generates revenue through comprehensive turnkey project contracts and standalone execution services, such as the supply and installation of specialised pharmaceutical equipment.
Growth Outlook
Growth is driven by the increasing demand for high-quality, regulatory-compliant pharmaceutical manufacturing infrastructure. The company leverages its technical expertise to capture opportunities in both greenfield projects and equipment upgrades.
Key Risks
- Regulatory Compliance Risk. Failure to meet stringent international pharmaceutical manufacturing standards could lead to project rejection or loss of client trust.
- Project Execution Risk. Delays in procurement or installation phases may result in cost overruns and impact the company's profitability on fixed-price contracts.
- Sector Cyclicality. The company's performance is heavily dependent on capital expenditure cycles within the global biopharmaceutical industry.
- Competitive Pressure. Intense competition from both domestic and international engineering firms may exert pressure on project margins.
Start your research today
Unlock AI insights, financials, peers and live data on Fabtech Technologies Limited and 5,000+ companies — free.
Key Metrics
P/E
10.9x
Q1 FY27 · consolidated
EV/EBITDA
9.1x
Q1 FY27 · consolidated
NET PROFIT MARGIN
5.6%
Q1 FY27 · consolidated
Peers · Healthcare Research, Analytics & Technology
| Company | Mkt Cap | P/E | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Fabtech Technologies LimitedFABTECH | ₹668 Cr | 10.87 | 9.14 | — | 16.3% | 11.6% | 14.1% | — |
Syngene International Ltd.SYNGENE | ₹15,969 Cr | 71.93 | 17.87 | -3.4% | 24.5% | 4.6% | 6.2% | -39.8% |
Indegene Ltd.INDGN | ₹14,493 Cr | 36.00 | 19.80 | 30.4% | 18.8% | 13.9% | 17.4% | +10.6% |
Suven Life Sciences LimitedSUVEN | ₹10,681 Cr | -25.39 | -30.90 | 17.3% | -557.4% | -100.5% | -99.8% | +78.6% |
Vimta LabsVIMTALABS | ₹2,839 Cr | 35.59 | 18.05 | 15.2% | 37.3% | 19.1% | 24.1% | -20.2% |
Take SolutionsTAKE | ₹204 Cr | 16.07 | 32.77 | — | 7.4% | 49.8% | 24.2% | +27.3% |
As of Q1 FY27
Financials
Fabtech Technologies Limited
BSE: FABTECH · Healthcare Research, Analytics & Technology
Snapshot
Unlock Fabtech Technologies Limited's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Fabtech Technologies Ltd is a biopharma engineering firm specialising in end-to-end turnkey solutions for pharmaceutical plants. Their services encompass the entire project lifecycle, including design, engineering, procurement, installation, and regulatory validation.
Business Model
The company generates revenue through comprehensive turnkey project contracts and standalone execution services, such as the supply and installation of specialised pharmaceutical equipment.
Growth Outlook
Growth is driven by the increasing demand for high-quality, regulatory-compliant pharmaceutical manufacturing infrastructure. The company leverages its technical expertise to capture opportunities in both greenfield projects and equipment upgrades.
Key Risks
- Regulatory Compliance Risk. Failure to meet stringent international pharmaceutical manufacturing standards could lead to project rejection or loss of client trust.
- Project Execution Risk. Delays in procurement or installation phases may result in cost overruns and impact the company's profitability on fixed-price contracts.
- Sector Cyclicality. The company's performance is heavily dependent on capital expenditure cycles within the global biopharmaceutical industry.
- Competitive Pressure. Intense competition from both domestic and international engineering firms may exert pressure on project margins.
Start your research today
Unlock AI insights, financials, peers and live data on Fabtech Technologies Limited and 5,000+ companies — free.
Key Metrics
P/E
10.9x
Q1 FY27 · consolidated
EV/EBITDA
9.1x
Q1 FY27 · consolidated
NET PROFIT MARGIN
5.6%
Q1 FY27 · consolidated
Peers · Healthcare Research, Analytics & Technology
As of Q1 FY27